

# 3D Genome Analysis Identifies Enhancer Hijacking Mechanism for High-Risk Factors in Human T-ALL

# Fengling Chen Supervisor: Michael Q. Zhang & Yang Chen

Bioinformatics Division and Center for Synthetic and Systems Biology, Department of Automation, Tsinghua University

2020-12-05



## **CML and GLIVEC**







Chronic myelogenous leukemia (CML) 90% CML patients have BCR-ABL translocation; GLIVEC can turn the five-year survival rate from 30% to 90%.





#### ETP-ALL

- 1. Block at the earliest stages of T cell differentiation;
- 2. High-risk subtype

Belver et al. Nature Reviews Cancer, 2016



#### Whole-exome and RNA sequencing analyses of large T-ALL cohorts



- Identification of T-ALL associated mutations and dysregulated genes.
- Non-coding region account for 98% genome, regulatory elements locate in non-coding region.

### How alternations of the non-coding region contribute to T-ALL progression?



## Motivation of studying T-ALL with 3D genome data



Mechanism of oncogene activation (Hnisz et al. Science, 2016)

**3D** genome technology is a great tool to detect non-coding alterations and explain the mechanism of oncogene activation.

## **Experimental design**



Prof. Hong Wu



Liang et al. Nature communication, 2018



Dr. Lu Yang

4 Healthy Donors





Paired BL-Hi-C and RNA-seq experiment



Compartment: B-to-A (1.38%) and A-to-B switches (1.59%) TAD boundaries: total: 3421; T-ALL-specific: 377; normal-specific:315 Loops: total: 38464; enhanced: 2330; reduced: 4073

# Chromatin structure changes coincide with oncogenic transcription factor aberrant expression



29.4% (996 /3392) of DEGs between normal and T-ALL were associated with consistent 3D genome alterations.



CDK6 is a potential target for T-ALL treatment



These could be the downstream of genetic variation.

#### Hi-C data reveal massive novel translocations



### Hi-C data reveal massive novel translocations



#### **Trans-loops forms between TLX3 and BCL11B enhancers**



TLX3 and BCL11B are both import TFs in T cell development.

## **Characteristics of trans-loops**



More DEGs can be found using trans-loops



Trans-loop tends to utilize original REs and CTCF binding sites.

## **Two HOXA activation mechanism**





## Translocation-mediated enhancer hijack leads to HOXA13 overexpression



HOXA13 were regulated by CDK6 enhancers via trans-loops.

## Translocation-mediated enhancer hijack leads to HOXA13 overexpression



HOXA13 were regulated by BCL11B and ERG enhancers via trans-loops.

#### **Trans-activation of HOXA related sophisticated loops**



#### **Trans-activation of HOXA related sophisticated loops**



### HOXA13 correlates with poor prognosis of pediatric T-ALL



The complete response rates: HOXA13+ (50%) and HOXA13- (92%) groups (p-value = 0.007419)

- 1. Systematically revealed the 3D genome landscape of T-ALL patients.
- 2. Uncovered novel translocations and neo-loops of T-ALL.
- 3. Demonstrated gene dysregulation in T-ALL by trans-activation and enhancer hijacking with HOXA as an example.
- 4. HOXA13 correlates with poor outcome.



Trans-activation of HOXA

Enhancer hijacking of HOXA

## Discussion

#### **Driver of subpopulation**



Chromatin conformation of T-ALL subpopulation is centered on oncogenic TFs ?

### **Genome variation ->key TF dysregulation->conformation->expression**

# Discussion



## Acknowledgement

#### Tsinghua University

Prof. Michael Zhang Yang Chen Minglei Shi

#### Key Collaborators

#### Peking University

Prof. Hong Wu Lu Yang Haichuan Zhu Bingjie Dong

#### Peking University People's Hospital

Xiaojun Huang Zongru Li Yongzhan Zhang Leping Zhang Qian Jiang Yan Chang

#### National Center for Protein Sciences Beijing

Yan Liu (Tsinghua University) Fei Wang (Peking University) Xuefang Zhang (Peking University)





